Table 1 Baseline characteristics of ITT patients
|  | Nivo + chemo | Chemo |
|---|---|---|
Characteristic | (n = 60) | (n = 30) |
Age (%) | 62.59 ± 7.48 | 65.10 ± 6.42 |
< 65 years | 33 (55) | 16 (53.3) |
≥ 65 years | 27 (45) | 14 (46.7) |
Gender (%) | Â | Â |
Female | 10 (16.7) | 4 (13.3) |
Male | 50 (83.3) | 26 (86.7) |
Tumor location (%) | Â | Â |
Upper thoracic | 9 (15) | 4 (13.3) |
Middle thoracic | 34 (56.7) | 16 (53.3) |
Lower thoracic | 17 (28.3) | 10 (16.7) |
BMI (%) | 22.63 ± 2.87 | 23.72 ± 2.50 |
≤ 25 | 42 (70) | 20 (66.7) |
> 25 | 10 (16.7) | 8 (26.7) |
NA | 8 (13.3) | 2 (6.6) |
ECOG (%) | Â | Â |
0 | 6 (10) | 1 (3.3) |
1 | 54 (90) | 29 (96.7) |
Median tumor diameter (mm) | 14.84 ± 5.21 | 14.78 ± 6.35 |
Median tumor length (mm) | 46.80 ± 18.76 | 45.44 ± 17.31 |
Clinical stage (%) | Â | Â |
cII | 10 (16.7) | 5 (16.7) |
cIII | 50 (83.3) | 25 (83.3) |
RECIST (%) | Â | Â |
PR | 52 (86.7) | 26 (86.7) |
SD | 4 (6.7) | 4 (13.3) |
PD | 3 (5) | 0 |
NA | 1 (1.6) | 0 |
PD-L1 expression – TPS (%) |  |  |
TPS < 1% | 30 (50) | 1 (3.3) |
TPS 1–49% | 15 (25) | 2 (6.7) |
Non-evaluable | 15 (25) | 27 (90) |
PD-L1 expression – CPS (%) |  |  |
CPS < 1 | 12 (20) | 0 |
CPS ≥ 1, < 5 | 20 (33.3) | 0 |
CPS ≥ 5, < 10 | 7 (11.7) | 2 (6.7) |
CPS ≥ 10 | 6 (10) | 1 (3.3) |
Non-evaluable | 15 (25) | 27 (90) |